Profile
ten23 health is a Swiss-based Contract Development, Manufacturing, and Testing Organization (CDMTO) focused on sterile pharmaceutical drug products. With high flexibility in batch size and container type, we are equipped to handle the services needed for small clinical runs to commercial-scale production, including low-volume, high-precision fills for different applications (biologics, peptides, small molecules, oligonucleotides).
We are B Corp certified and rank in the top 3% of our industry on EcoVadis. Our approach is guided by validated science-based targets and aligned with the Voluntary Sustainability Reporting Standard for non-listed SMEs (VSME). We work with My Green Lab to support sustainable practices in scientific environments. Explore our Fairstainability Report, summarizing key milestones and measurable results.
Our services include:
- Development – such as formulation development
- Manufacturing services (fill and finish) – such as sterile filling into syringes, vials, or cartridges for clinical or commercial GMP use
- Analytical testing and quality control – such as method development or characterization
ten23 solely operates as a B2B services business and has no internal product pipeline. We support device selection and integration – both glass and polymer containers – and enable integration with advanced drug delivery systems like West’s SmartDose® and Ypsomed’s YpsoDose® for subcutaneous applications.
Key focus areas include:
- Intravitreal: Ultra-low volume fills and packaging safety
- Subcutaneous: Large-volume device transitions and usability optimization
- Lyophilized and liquid formats: Developed with freeze-thaw stability in mind
We serve a wide range of clients in North America, Europe, and Asia, from large pharmaceutical companies to small academic spinouts. Ongoing collaborations include the top 10 large pharma by revenue, but our major base is medium-sized enterprises that are on the cusp of clinical entry. These companies choose ten23 for our scientific excellence and comprehensive, holistic drug product service offerings. Customers often remain with us throughout the full development lifecycle, from early trials through to late-phase development and commercial product launches.
In just a few years since our foundation in 2021, ten23 health has rapidly expanded with over 200 employees and launched state-of-the-art facilities (BASE® and VIVA®). Under the leadership of our founder and CEO, Prof. Dr. Hanns-Christian Mahler, ten23 is anchored by an exceptional team with exceptional industry expertise. Our team members have contributed to the commercialization of prominent products such as Ocrevus, Ocrevus SC, Tecentriq, Tecentriq SC, Herceptin SC, Kadcyla, Xolair, Vabysmo, Actemra, Gazyva, Polivy, Eylea, Praluent, Adakveo, Ilaris, and Beovu, showcasing their skill in navigating rigorous regulatory requirements.
Our services:
Pharmaceutical product development
We believe that pharmaceutical products should be designed with the end goal in mind in order to deliver safe, effective, high-quality, and easy-to-use medicines for patients. At ten23 health, we support clients in sterile drug product development in a wide range of therapeutic modalities, and integrate different processes of drug product development such as formulation development, manufacturing process design, primary packaging, and device selection. Furthermore, we carefully develop analytical methods for an appropriate control strategy to achieve a global pharmaceutical product design from the outset. We operate with Biosafety Level BSL1 and BSL2 compliant development labs.
Drug product manufacturing
Drug product manufacturing is more than filling containers. We design, characterize, and validate the sterile product manufacturing process, and also manufacture clinical and commercial sterile drug products according to cGMP using the most modern isolator technology. Our focus is on delivering safe and high-quality sterile drug products, enabling convenient application for patients.
Analytical testing and quality control services
ten23 health offers comprehensive analytical testing and quality control (QC) services across its Basel and Visp sites, ensuring robust analytical and microbiological support throughout the drug development and manufacturing lifecycle. At its Swissmedic-approved GMP testing facility in Basel, ten23 health performs clinical and commercial release and stability testing for both drug substances (DS) and drug products (DP). This includes the transfer, validation, and verification of analytical methods, including those handed over from development, as well as method development within ISO 9001:2015 certified laboratories.
ten23 health operates three complementary facilities in Switzerland which are designed to support the full lifecycle of sterile injectable drug products. The BASE® site in Basel serves as the hub for formulation, process, analytical development, and non-GMP manufacturing (Line 0) for stability and preclinical studies. The VIVA1® site in Visp is dedicated to GMP-compliant aseptic manufacturing, including fill-finish operations, cold storage, visual inspection, and assembly. The newest facility, VIVA2® in Visp, extends ten23’s capacity with large-scale GMP fill-finish for both liquid and lyophilized formats, ready-to-use syringes and cartridges, and integrates sustainable infrastructure, such as solar-powered energy systems. Together, these facilities enable end-to-end support from development through commercial supply, underpinned by regulatory compliance and operational flexibility.